Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -95.44 | -78.22 | -- |
| EBIT | 3.43 | 13.30 | 4.00 | -206.31 | -- |
| Net Profit | 3.23 | 11.78 | 3.13 | -241.65 | -- |
| EPS | 3.23 | 44.49 | 32.86 | -150.79 | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -1,571.27 | -- | -19,724.69 | -- | -911.99 |
| Net Margin
| 31.04 | -- | -21,376.54 | -- | -- |
| Return on equity
| 1,274.17 | -- | -- | 3,771.56 | -122.07 |
| Return on Capital
| -54.80 | -- | -- | -183.99 | -42.05 |
| Return on Assets
| -43.60 | -- | -68.38 | -144.34 | -31.10 |
| Debt to Equity (x)
| -- | -- | 0.00 | -3.55 | 5.21 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
--
|
-183.99
|
-42.05
|
61.65
|
185.21
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
--
|
3,771.56
|
-122.07
|
173.01
|
-221.01
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-68.38
Lower than Peers by 37.41
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
-68.38
|
-144.34
|
-31.10
|
44.65
|
130.38
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-19,724.69
Lower than Peers by 19,641.07
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
-19,724.69
|
--
|
-911.99
|
-2,230.56
|
37.85
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-21,376.54
Lower than Peers by 21,283.87
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
-21,376.54
|
--
|
-363.83
|
31.04
|
33.84
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-0.19
Lower than Peers by 0.19
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
-0.19
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-95.44
Lower than Peers by 149.39
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
-95.44
|
-1.00
|
1.48
|
-0.97
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
4.00
Higher than Peers by 4.80
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
4.00
|
-1.51
|
-1.59
|
-300.67
|
156.05
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
3.13
Higher than Peers by 10.43
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
3.13
|
-177.02
|
-181.83
|
11.17
|
147.79
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
32.86
Higher than Peers by 18.21
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
32.86
|
-0.73
|
-1.79
|
-0.59
|
--
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
110.81
Higher than Peers by 120.99
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
110.81
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
--
|
-3.55
|
5.21
|
1.16
|
13.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
24.27
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
24.27
|
-3.55
|
5.19
|
0.00
|
6.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.03
Lower than Peers by 4.78
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
1.03
|
0.77
|
1.12
|
13.30
|
1.89
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
1.03
Lower than Peers by 4.67
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
1.03
|
--
|
1.12
|
13.32
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-10.62
Lower than Peers by 8.54
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
-10.62
|
-11.27
|
-14.39
|
-18.08
|
11.92
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
10.49
Lower than Peers by 8.65
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
10.49
|
--
|
0.76
|
6.99
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.00
Lower than Peers by 0.06
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
0.00
|
--
|
0.09
|
0.04
|
3.85
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
--
|
--
|
6.53
|
25.54
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
--
|
-88.84
|
-437.61
|
-1,521.88
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
--
|
6,278.35
|
6,898.40
|
6,566.89
|
1,078.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
--
|
--
|
-7,329.48
|
-8,063.22
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
--
|
-0.03
|
-0.06
|
0.85
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.00
Lower than Peers by 5.18
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
0.00
|
-0.22
|
0.18
|
0.77
|
--
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.41
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
-0.41
|
-0.10
|
0.16
|
0.51
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
0
Lower than Peers by 146
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
eFFECTOR Therapeutics (EFTR)
|
0
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|